1. Home
  2. INOD vs DFTX Comparison

INOD vs DFTX Comparison

Compare INOD & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innodata Inc.

INOD

Innodata Inc.

HOLD

Current Price

$44.30

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$15.68

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
INOD
DFTX
Founded
1988
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
1993
N/A

Fundamental Metrics

Financial Performance
Metric
INOD
DFTX
Price
$44.30
$15.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$91.67
$33.00
AVG Volume (30 Days)
1.6M
1.8M
Earning Date
02-26-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
62.46
N/A
EPS
1.01
N/A
Revenue
$238,467,000.00
N/A
Revenue This Year
$48.85
N/A
Revenue Next Year
$25.93
N/A
P/E Ratio
$43.97
N/A
Revenue Growth
73.57
N/A
52 Week Low
$26.41
$4.70
52 Week High
$93.85
$18.70

Technical Indicators

Market Signals
Indicator
INOD
DFTX
Relative Strength Index (RSI) 37.12 42.61
Support Level $41.34 $16.17
Resistance Level $49.60 $17.80
Average True Range (ATR) 4.64 1.15
MACD -1.21 -0.13
Stochastic Oscillator 12.95 4.38

Price Performance

Historical Comparison
INOD
DFTX

About INOD Innodata Inc.

Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: